companies / medcurainc-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-05 json
| total_raised | 38,286,41038.3M | ○ |
|---|---|---|
| founded | null | |
| hq | Riverdale, Maryland | |
| industry | unknown | |
| stage | null |
Medcura develops biopolymer hemostatic products that mechanically coat bleeding sites to control surgical, trauma, and consumer bleeding, led by its LifeGel gel for spine surgery. It serves surgeons, trauma settings, and payers seeking lower-cost hemostasis. Its edge is a flowable gel that resists swelling, with FDA Breakthrough Device designation.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-07-25 | Funding round | 38,286,41038.3M | null | ○ |
@sentry/browser, cloudflare, google font api, google hosted libraries, hsts, http/3, jquery 3.5.1, wistia
| fact | status | src |
|---|---|---|
| Funding round, $38.3M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-25latest_round: seed, $38.3M, 2025-07-25 → Funding round, $38.3M, 2025-07-25, ○ 2026-06-05 | latest_round | seed, $38.3M, 2025-07-25 → Funding round, $38.3M, 2025-07-25 | ○ 2026-06-05 |
Records begin 2026-09-24. all_changes